Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia―Pacific trial
- Author
- CHENG, Ann-Lii1 ; ZHONGZHEN GUAN2 ; JIANMING XU11 ; FANG FANG12 ; ZOU, Jessie12 ; LENTINI, Giuseppe13 ; VOLIOTIS, Dimitris12 ; KANG, Yoon-Koo14 ; ZHENDONG CHEN3 ; TSAO, Chao-Jung4 ; SHUKUI QIN5 ; JUN SUK KIM6 ; YANG, Tsai-Sheng7 ; WON YOUNG TAK8 ; HONGMING PAN9 ; SHIYING YU10
[1] National Taiwan University Hospital, Taipei, Taiwan, Province of China
[2] Sun Yat-sen University Cancer Centre, Guangzhou, China
[3] First Affiliated Hospital of Anhui Medical University Hefei, China
[4] Chi Mei Medical Centre, Liou Ying Campus, Tainan, Taiwan, Province of China
[5] Nanjing Bayi Hospital, Nanjing, China
[6] Korea University Guro Hospital, Seoul, Korea, Republic of
[7] Chang Gung Memorial Hospital, Tao-Yuan, Taiwan, Province of China
[8] Kyungpook National University Hospital, Daegu, Korea, Republic of
[9] Sir Run Run Shaw Hospital, Zhejiang, China
[10] Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
[11] Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China
[12] Bayer HealthCare Pharmaceuticals, Montville, NJ, United States
[13] Bayer Schering Pharma, Wuppertal, Germany
[14] ASAN Medical Center, Songpa-gu, Seoul, Korea, Republic of - Source
European journal of cancer (1990). 2012, Vol 48, Num 10, pp 1452-1465, 14 p ; ref : 34 ref
- ISSN
- 0959-8049
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Elsevier, Kidlington
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- Hepatocellular carcinoma Sorafenib Subset analyses
- Keyword (fr)
- Antiangiogénique Anticancéreux Cancer du foie Cancérologie Carcinome hépatocellulaire Chimiothérapie Efficacité traitement Essai clinique phase III Homme Sorafénib Stade avancé Asie Cancer Inhibiteur de la tyrosine kinase Inhibiteur enzyme Inhibiteur multikinase Pathologie de l'appareil digestif Pathologie du foie Traitement Tumeur maligne
- Keyword (en)
- Antiangiogenic agent Antineoplastic agent Liver cancer Cancerology Hepatocellular carcinoma Chemotherapy Treatment efficiency Phase III trial Human Sorafenib Advanced stage Asia Cancer Tyrosine kinase inhibitor Enzyme inhibitor Multikinase inhibitor Digestive diseases Hepatic disease Treatment Malignant tumor
- Keyword (es)
- Antiangiogenico Anticanceroso Cáncer del hígado Cancerología Carcinoma hepatocelular Quimioterapia Eficacia tratamiento Ensayo clínico fase III Hombre Sorafenib Estadio avanzado Asia Cáncer Inhibidor tyrosine kinase Inhibidor enzima inhibidor multicinasa Aparato digestivo patología Hígado patología Tratamiento Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments
- Discipline
- General pharmacology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 26037596
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.ejca.2011.12.006 
https://dx.doi.org/10.1016/j.ejca.2011.12.006
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1016\/j.ejca.2011.12.006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2015Pacific trial\";s:9:\"\u0000*\u0000jtitle\";s:33:\"European journal of cancer (1990)\";s:9:\"\u0000*\u0000stitle\";s:21:\"Eur. j. cancer (1990)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1452\";s:8:\"\u0000*\u0000epage\";s:4:\"1465\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0959-8049\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"CHENG\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Ann-Lii\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:14:\"ZHONGZHEN GUAN\";i:1;s:11:\"JIANMING XU\";i:2;s:9:\"FANG FANG\";i:3;s:11:\"ZOU, Jessie\";i:4;s:17:\"LENTINI, Giuseppe\";i:5;s:18:\"VOLIOTIS, Dimitris\";i:6;s:14:\"KANG, Yoon-Koo\";i:7;s:13:\"ZHENDONG CHEN\";i:8;s:15:\"TSAO, Chao-Jung\";i:9;s:10:\"SHUKUI QIN\";i:10;s:11:\"JUN SUK KIM\";i:11;s:16:\"YANG, Tsai-Sheng\";i:12;s:13:\"WON YOUNG TAK\";i:13;s:12:\"HONGMING PAN\";i:14;s:10:\"SHIYING YU\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2015Pacific trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1016\/j.ejca.2011.12.006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2015Pacific trial\";s:9:\"\u0000*\u0000jtitle\";s:33:\"European journal of cancer (1990)\";s:9:\"\u0000*\u0000stitle\";s:21:\"Eur. j. cancer (1990)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1452\";s:8:\"\u0000*\u0000epage\";s:4:\"1465\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0959-8049\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"CHENG\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Ann-Lii\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:14:\"ZHONGZHEN GUAN\";i:1;s:11:\"JIANMING XU\";i:2;s:9:\"FANG FANG\";i:3;s:11:\"ZOU, Jessie\";i:4;s:17:\"LENTINI, Giuseppe\";i:5;s:18:\"VOLIOTIS, Dimitris\";i:6;s:14:\"KANG, Yoon-Koo\";i:7;s:13:\"ZHENDONG CHEN\";i:8;s:15:\"TSAO, Chao-Jung\";i:9;s:10:\"SHUKUI QIN\";i:10;s:11:\"JUN SUK KIM\";i:11;s:16:\"YANG, Tsai-Sheng\";i:12;s:13:\"WON YOUNG TAK\";i:13;s:12:\"HONGMING PAN\";i:14;s:10:\"SHIYING YU\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2015Pacific trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:26:\"10.1016\/j.ejca.2011.12.006\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1016\/j.ejca.2011.12.006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2015Pacific trial\";s:9:\"\u0000*\u0000jtitle\";s:33:\"European journal of cancer (1990)\";s:9:\"\u0000*\u0000stitle\";s:21:\"Eur. j. cancer (1990)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1452\";s:8:\"\u0000*\u0000epage\";s:4:\"1465\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0959-8049\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"CHENG\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Ann-Lii\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:14:\"ZHONGZHEN GUAN\";i:1;s:11:\"JIANMING XU\";i:2;s:9:\"FANG FANG\";i:3;s:11:\"ZOU, Jessie\";i:4;s:17:\"LENTINI, Giuseppe\";i:5;s:18:\"VOLIOTIS, Dimitris\";i:6;s:14:\"KANG, Yoon-Koo\";i:7;s:13:\"ZHENDONG CHEN\";i:8;s:15:\"TSAO, Chao-Jung\";i:9;s:10:\"SHUKUI QIN\";i:10;s:11:\"JUN SUK KIM\";i:11;s:16:\"YANG, Tsai-Sheng\";i:12;s:13:\"WON YOUNG TAK\";i:13;s:12:\"HONGMING PAN\";i:14;s:10:\"SHIYING YU\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2015Pacific trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1016\/j.ejca.2011.12.006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2015Pacific trial\";s:9:\"\u0000*\u0000jtitle\";s:33:\"European journal of cancer (1990)\";s:9:\"\u0000*\u0000stitle\";s:21:\"Eur. j. cancer (1990)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1452\";s:8:\"\u0000*\u0000epage\";s:4:\"1465\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0959-8049\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"CHENG\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Ann-Lii\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:14:\"ZHONGZHEN GUAN\";i:1;s:11:\"JIANMING XU\";i:2;s:9:\"FANG FANG\";i:3;s:11:\"ZOU, Jessie\";i:4;s:17:\"LENTINI, Giuseppe\";i:5;s:18:\"VOLIOTIS, Dimitris\";i:6;s:14:\"KANG, Yoon-Koo\";i:7;s:13:\"ZHENDONG CHEN\";i:8;s:15:\"TSAO, Chao-Jung\";i:9;s:10:\"SHUKUI QIN\";i:10;s:11:\"JUN SUK KIM\";i:11;s:16:\"YANG, Tsai-Sheng\";i:12;s:13:\"WON YOUNG TAK\";i:13;s:12:\"HONGMING PAN\";i:14;s:10:\"SHIYING YU\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2015Pacific trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.1016\/j.ejca.2011.12.006\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2015Pacific trial\";s:9:\"\u0000*\u0000jtitle\";s:33:\"European journal of cancer (1990)\";s:9:\"\u0000*\u0000stitle\";s:21:\"Eur. j. cancer (1990)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"48\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1452\";s:8:\"\u0000*\u0000epage\";s:4:\"1465\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0959-8049\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"CHENG\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Ann-Lii\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:14:\"ZHONGZHEN GUAN\";i:1;s:11:\"JIANMING XU\";i:2;s:9:\"FANG FANG\";i:3;s:11:\"ZOU, Jessie\";i:4;s:17:\"LENTINI, Giuseppe\";i:5;s:18:\"VOLIOTIS, Dimitris\";i:6;s:14:\"KANG, Yoon-Koo\";i:7;s:13:\"ZHENDONG CHEN\";i:8;s:15:\"TSAO, Chao-Jung\";i:9;s:10:\"SHUKUI QIN\";i:10;s:11:\"JUN SUK KIM\";i:11;s:16:\"YANG, Tsai-Sheng\";i:12;s:13:\"WON YOUNG TAK\";i:13;s:12:\"HONGMING PAN\";i:14;s:10:\"SHIYING YU\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia\u2015Pacific trial\";s:8:\"\u0000*\u0000place\";s:10:\"Kidlington\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
